Semaglutide's Potential to Treat Fatty Liver Disease in Obese and Diabetic Patients

Nonalcoholic Fatty Liver Disease (NAFLD) is a prevalent chronic liver condition, often associated with obesity and type 2 diabetes mellitus (T2DM). It can progress to more severe forms like nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even liver cancer. While lifestyle modifications are primary, effective pharmacological treatments for NAFLD are urgently needed. This clinical trial specifically investigates the therapeutic efficacy of Semaglutide in improving NAFLD and its associated complications in individuals already suffering from obesity and/or T2DM.

As a recently completed clinical trial (completion date: April 1, 2024), specific quantitative results regarding Semaglutide's efficacy in NAFLD are currently pending publication. However, the study was rigorously designed to assess improvements in liver health. Researchers aimed to demonstrate significant reductions in liver steatosis (fat accumulation) and fibrosis (scarring) as measured by Fibroscan parameters (liver stiffness in kPa, steatosis in dB/m). They also sought to show favorable changes in calculated fibrosis scores like FIB-4 and NAFLD Fibrosis Score, which integrate various clinical markers. The primary goal was to quantify the extent to which Semaglutide, in both oral and subcutaneous forms, could reverse or mitigate NAFLD progression in patients with obesity and/or type 2 diabetes mellitus. The study's main objective was to determine if Semaglutide could effectively improve NAFLD and its sequelae in patients with obesity and/or type 2 diabetes mellitus.